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EDITORIAL Open Access
Filling the gaps in global antimicrobial
resistance research/surveillance
Luis Furuya-Kanamori1* and Laith Yakob2*
There is a large clinical and public health burden associ-
ated with antimicrobial resistance (AMR). This burden
is likely to increase over time and urgent action is re-
quired [1, 2]. In a recent review, it was estimated that
AMR could cause 10 million deaths a year by 2050 [3].
However, there are major uncertainties associated with
this estimate [4], not least of all the patchiness of sur-
veillance data especially when it comes to developing
countries.
A collection of new articles has been brought together
in this special issue for BMC Infectious Diseases. This
journal being an obvious hub for this type of research:
being open access broadens the audience; and the board
of committed, expert editors lends rigour to the science
that is communicated. Emphasis has been placed on pre-
senting latest results pertaining to AMR from around
the world. Going to press, this special issue already has
articles from a dozen countries spanning Latin America,
Europe, West-to-East Africa, the Middle East, South and
East Asia.
The criticality of surveillance in AMR is widely ac-
knowledged and all of the articles of the special issue fall
under this umbrella term, across very different scales,
ranging from Irenge et al. [5] reporting on multidrug-
resistant (MDR) E. coli in local healthcare facilities in
South Kivu province of the Democratic Republic of
Congo to Galani et al. [6] reporting nationwide hospital
carbapenem resistant K. pneumoniae survey for Greece.
Comprising one of the five strategic priorities of the
Global Action Plan (GAP) on AMR [7], a recent report
from the Interagency Coordination Group on Anti-
microbial Resistance [8] describes several ways in which
surveillance can support efforts to reduce AMR:
i) detect the emergence and prevalence of AMR
e.g. Nelson et al. [9] developed a rapid cost-effective
molecular detection test for macrolide resistance
that can be implemented in clinical settings. Sur-
veillance studies at a national [6], regional [10], and
local [5] level have exposed the magnitude of
the AMR problem around the world.
ii) guide patient treatment e.g. Arevalo-Jaimes et al.
[11] found 38% of Colombian patients with H. pyl-
ori were resistant to first line drug clarithromycin,
calling into question the appropriateness of the
current, standard triple therapy. Likewise, Mashe
et al. [12] found that 88% of S. typhi in Zimbabwe
were resistant to two or more first line drugs indi-
cating the need for changes in their current
guidelines.
iii) identify populations at risk e.g. Milovanovic et al.
[13] found that more than half of patients with liver
cirrhosis in Serbian tertiary care facilities that
contracted hospital-acquired urinary tract infections
were infected with MDR strains, calling for individ-
ualized protocols for treatment of these immuno-
compromised populations.
iv) inform policy development e.g. Haddad et al. [14]
from the Lebanese Society of Infectious Diseases
and Clinical Microbiology publish new guidelines
for empiric and targeted antimicrobial therapy of
complicated intra-abdominal infections based on
risk factors, site of acquisition of infection, and clin-
ical severity of illness.
v) assess the impact of interventions. Although
there were many studies that investigated the
current state of AMR to plan interventions, none
described intervention effectiveness.
This being a rolling special issue, our coverage is ex-
pected to expand even further and continue spotlighting
findings from regions of the world for which data are
largely absent, and yet most necessary according to bur-
den projections [3]. Given its conspicuous absence both
from this special issue as well as the wider literature, we
particularly encourage the submission of articles that as-
sess AMR intervention effectiveness.
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